The concentrations of inhibin and follistatin in amniotic fluid and in tissue extracts from the placenta, gonads and adrenals of fetal sheep were measured using radioimmunoassays. These tissue extracts were from whole fetuses from days 16 to 45 and from the individual organs from day 46 to 145 (term) and were assayed at multiple dilutions. The capacity of these extracts to alter FSH production of rat anterior pituitary cells in culture was also assessed at multiple dilutions.
gestation stimulated FSH secretion in the pituitary cell bioassays, suggesting the presence of activin which was confirmed by the measurement of immunoactive activin (13\ m=. \ 3\ m=+-\ 2\ m=. \ 5ng/ml) in a specific radioimmunoassay.
Maximum concentrations of immunoactive and bioactive inhibin in placental extracts were observed in late gestation (2\m=.\2 \m=+-\0\m=.\6and 3\m=.\8\m=+-\1\m=.\6 ng/g respectively) and there was no significant difference between sexes. Follistatin concentrations in placental cotyledons ranged from 11\m=.\5to 27\m=.\1 ng/g with no significant difference between sexes. In view of the higher follistatin concentrations compared with inhibin, it is likely that the capacity of placental extracts to suppress FSH production by pituitary cells in culture is due predominantly to follistatin.
Immunoactive inhibin was observed in high concentrations in the fetal testis throughout gestation; with concentrations increasing to a maximum of 1993\m=.\0\m=+-\519\m=.\7ng/g at 126\p=n-\135 days of gestation with a ratio of bioactive: immunoactive inhibin of 1:20. Although bioactive and immunoactive inhibin was also observed in fetal ovaries and adrenals from both male and female fetuses, concentrations were lower than those observed in fetal testes. Follistatin concentrations in the fetal testis were elevated between 70 and 95 days (97\m=.\6ng/g) and then declined. Similar concentrations were found in the adrenal glands of both sexes (males 83\m=.\5\p=n-\103\m=.\3 ng/g: females 55\ m=. \ 3\ p=n-\ 95\m=.\8 ng/g). In both males and females, immunoactive inhibin concentrations in fetal adrenals increased during gestation peaking at levels of 34\m=.\4\m=+-\16\m=.\5and 27\m=.\8\m=+-\ 9\m=.\0ng/g respectively. These data suggest that the capacity of adrenal extracts to suppress FSH production by pituitary cells is due to both inhibin and follistatin.
These studies demonstrated that significant concentra-
Introduction
The isolation of inhibin A and B from bovine and porcine follicular fluid (Ling et al. 1985 , Robertson et al. 1985 and subsequently partial purification of inhibin A from ovine follicular fluid (Leversha et al. 1987 ) was followed by the development of radioimmunoassays to facilitate the deter¬ mination of inhibin concentrations in biological fluids (McLachlan et al. 1986 ). Such assays have proved valuable in establishing the sites of production of inhibin and
The specificity of the radioimmunoassays used in these studies has been questioned because of the recent identi¬ fication of monomeric products of the subunit which cross-react in the assays (Robertson eí (Grootenhuis et al. 1990 , Hancock et al. 1992 and in the bovine fetal testis in late gestation (Torney et al. 1990 (Torney et al. , 1992 .
Several studies have demonstrated the presence of inhibin , ß and ß subunit mRNA in multiple sites in the primate, rat and bovine fetus (Rabinovici et al. 1991 , Torney et al. 1992 ). However, the nature of the proteins secreted by these tissues has not been established nor has the presence of follistatin been assessed.
The recent availability of follistatin (Klein et al. 1991 ) and activin radioimmunoassays (Finney 1978) 
Inhibin, follistatin and activin concentrations in amniotic fluid
Immunoactive inhibin concentrations in amniotic fluid from male fetuses were 0-7 ±0-1 ng/ml at the gestational age range of 46-55 days and increased 12-fold (P<0-001) to a maximum of 11·2± 1-9 ng/ml at 116-125 days of gestation. There was no further increase in amniotic fluid immunoactive inhibin concentrations from this stage of gestation to term (Fig. 1) . The levels of immunoreactive inhibin in amniotic fluid from female fetuses at 46-55 days of gestation (0-4 ±0-2 ng/ml) increased fivefold ( <0 01) during gestation to reach maximum concentrations of 3-9 ±1-5 ng/ml at 126 ±135 days of gestation. Concen¬ trations at term in amniotic fluid from female fetuses were significantly ( <0 01) lower than those observed in males at the same gestational ages (Fig. 1) radioimmunoassay and showed levels of 13-3 ±2-5 ng/ml (n = 3) of immunoactive activin.
There was no significant difference in follistatin levels in amniotic fluid throughout gestation or between sexes (Fig. 2) , and the overall mean levels were 3-0 ±0-9 ng/ml for males and 3-7 ± 0-9 ng/ml for the females.
Inhibin and follistatin concentrations in placental cotyledons
Homogenates of the entire fetal membrane consisting of amniotic, allantoic and chorionic membranes and developing fetal cotyledons from fetuses prior to gonadal differentiation between days 26 and 45 of gestation con¬ tained detectable levels of immunoactive inhibin of 4-3 ±0-6 and 4-6 ±1-0 ng/g at days 26-35 and 36-45 respectively.
Placental cotyledons from male fetuses contained im¬ munoactive inhibin concentrations of 2-2 ±0-6 ng/g at days 46-55 of gestation and there was no significant change in immunoactive inhibin concentrations at any gestational age range studied. Immunoactive inhibin con¬ centrations were not significantly different between sexes (Fig. 3) . A similar pattern of immunoactive inhibin con¬ centrations was observed in female fetuses.
When placental extracts from male fetuses were added to the pituitary cell bioassay they caused a suppression of the FSH cell content which was equivalent to 1-00 ±0-1 ng inhibin/g at days 46-55 and increased significantly ( <0·05) to 38 ± 1-6 ng/g at days 116-125 of gestation. A similar pattern in the capacity of placental extracts from female fetuses to suppress FSH was observed (Fig. 3) . There was no significant difference between sexes in the capacity of extracts to suppress FSH production in the pituitary cell bioassay.
To determine whether the FSH suppression was due entirely to inhibin or in part to the presence of follistatin, the placental cytosols were assayed in the follistatin radio¬ immunoassay. In female fetuses, placental follistatin con¬ centrations ranged from 14-8 ± 1-7 ng/g at 135 days to 27-1 ng/g at 75 days with no significant differences at each of the time-points. In male fetuses, placental cotyledon follistatin levels ranged from 1T5 ± 1-0 ng/g at 65 days to 25-2 ±2-4 ng/g at 105 days with no group showing a significant change.
Inhibin and follistatin concentrations in whole fetuses at days 20-50 ofgestation Immunoactive inhibin concentrations increased signifi¬ cantly ( <0 1) in whole fetuses between days 16-25 and 46-55 of gestation from T9±0-3 ng/g at days 16-25 to 5-0 ±0-8 ng/g at days 46-55 of gestation. A significant (P<0-05) increase was also measured in the capacity of fetal extracts to suppress FSH between days 26-35 and 46-55 of gestation with levels, expressed as an inhibin potency, rising from 2-6 ±0-4 ng/g to 12-4 ±3-8 ng/g respectively (Fig. 4) .
In contrast to the rise found in inhibin concentrations, follistatin concentrations in the whole fetus decreased from 65-4 ±4-2 ng/g at 26-45 days to 14-1 ±0-7 ng/g at 46-55 days (Fig. 5) (Fig. 4) exist between the increases in inhibin concentrations in the amniotic fluid and the rise found in the testis concentrations.
The capacity of testis extracts to suppress FSH in the bioassay (Fig. 4) (Fig. 4) .
As the amount of testicular cytosol available to measure follistatin levels in this study was limited, we made two pools, each consisting of equal aliquots from four animals at each time-point. Follistatin concentrations increased from 14T ng/g at 55 days to peak at 976 ng/g at 95 days decreasing thereafter to 25 ng/g at 115 days (Fig. 5) (Fig. 6) . The capacity to suppress FSH expressed as bioactive inhibin levels was determined for the 76-85, 106-155 and 136-145 days of gestation age groups and levels were 14-7 ± 4-4, 18-9 ± 5-9 and 15-7 ±3-5 ng/g respectively. These values did not differ statistically between the different age groups.
In female fetuses, adrenal immunoactive inhibin con¬ centrations also increased significantly (P<0-05) from a nadir at days 76-85 to reach maximum concentrations between 136 and 145 days of gestation (27-8 ±9-0 ng/g). These were not significantly higher than those observed early in gestation (Fig. 6 ). FSH suppression expressed as 'bioactive inhibin' levels at 76-85, 86-95 and 126-135 days of gestation was 7 ±2-3, 5 ±2·8 and 9-2 ±2T ng/g respectively and was not significantly dif¬ ferent between groups (Fig. 6) . No statistically significant differences were found between immunoactive or bio¬ active inhibin concentrations in the adrenals of different sexes.
To determine if the FSH suppression seen in the bioassays was due to inhibin alone or in part to the presence of follistatin, the levels of follistatin were measured in pooled samples of adrenal cytosol extracts. The results obtained from samples from male fetuses at gestational ages 76-85, 106-135 and 136-145 days were 103-3 ±5-8, 83-5 ±0-9 (P<0-05 compared with 103-3 ±5-8) and 96-1 ±2-2 ng/g respectively, the results in the 106-135 day group being significantly ( <0 5) lower than in the 76-85 day group. In the female samples, the results from age groups at 76-85, 86-95 and 126-135 days were 95-9 ± 2-0, 80-8 ± 3-8 and 55-3 ±3-5 ng/g (each significantly ( <0 5) different).
Discussion
The most striking observation in this study was amniotic fluid may contain substantial concentrations of FSH-releasing substances which interfere in the assay. The presence of detectable activin concentrations by radio¬ immunoassay and bioassay confirms that amniotic fluid contains activin, although the levels measured may be an underestimate due to the potential interference of folli¬ statin in the radioimmunoassay and both follistatin and inhibin in the bioassay. These results do, however, con¬ firm that activin is present in amniotic fluid and can express its bioactivity as shown by its FSH-stimulatory activity in the presence of inhibin and follistatin. Since activin has been implicated in mesodermal induction (Thomsen et al. 1990 ) and in other developmental processess (Rabinovici et al. 1991, Roberts et As with studies on human placental extracts (McLachlan et al. 1986 , Petraglia et al. 1987 ) the sex of the fetus had no significant effect on placental immunoactive inhibin content. Although inhibin has been localized to both the cytotrophoblast and the syncytiotrophoblast in man (Petraglia et al. 1987 (Petraglia et al. , 1990 (Petraglia et al. , 1992 
